Rhythm Pharmaceuticals (RYTM) Goodwill & Intangibles (2021 - 2026)

Rhythm Pharmaceuticals (RYTM) has reported Goodwill & Intangibles for 6 consecutive years, with $5.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Goodwill & Intangibles fell 14.33% year-over-year to $5.1 million; the TTM figure through Mar 2026 stood at $5.1 million (down 14.33% YoY), while the FY2025 annual figure was $5.3 million, down 13.85% from the prior year.
• Goodwill & Intangibles fell to $5.1 million in Q1 2026 per RYTM's latest filing, from $5.3 million in the prior quarter.
• Across five years, Goodwill & Intangibles topped out at $8.5 million in Q1 2022 and bottomed at $5.1 million in Q1 2026.
• Historically, Goodwill & Intangibles has averaged $6.8 million across 5 years, with a median of $6.8 million in 2024.
• Annual changes were most pronounced in 2022 — Goodwill & Intangibles surged 70.54% — and 2026, when it retreated 14.33%.
• Rhythm Pharmaceuticals' Goodwill & Intangibles stood at $7.9 million in 2022, then slipped by 10.85% to $7.0 million in 2023, then retreated by 12.15% to $6.2 million in 2024, then retreated by 13.85% to $5.3 million in 2025, then slipped by 4.0% to $5.1 million in 2026.
• Business Quant data shows RYTM's Goodwill & Intangibles at $5.1 million in Q1 2026, $5.3 million in Q4 2025, and $5.5 million in Q3 2025.